Name (Synonyms) | Correlation | |
---|---|---|
drug1184 | SARS-CoV-2 convalescent plasma Wiki | 0.58 |
drug335 | Colchicine Wiki | 0.41 |
There is one clinical trial.
To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
Description: Cumulative incidence measured as the proportion of subjects who were hospitalized or who died prior to hospitalization
Measure: Cumulative incidence of hospitalization or death prior to hospitalization Time: Up to day 28Description: Cumulative incidence measured as the proportion of subjects experiencing an Serious Adverse Event (SAE).
Measure: Cumulative incidence of treatment-related serious adverse events Time: Up to day 28Description: Cumulative incidence measured as the proportion of subjects experiencing a Grade 3 or higher.
Measure: Cumulative incidence of treatment-related grade 3 or higher adverse events Time: Up to day 90Description: Analysis of serum SARS-CoV-2 antibody titers will also primarily be descriptive, comparing the geometric mean titers at day 0, 14, 28 and 90 between the randomized arms and calculating the shift or change in the titer distribution.
Measure: Change in serum SARS-CoV-2 antibody titers Time: Days 0, 14, 28 and 90Description: Duration in days of SARS-CoV-2 PCR time to negativity will be analyzed by calculating the number of days taken for a positive participant to lose positivity from day 0 to day 28.
Measure: Time to SARS-CoV-2 Polymerase Chain Reaction (PCR) negativity Time: Up to day 28Description: Change in levels of SARS-CoV-2 RNA between randomized arms from Day 0 to Day 28.
Measure: Change in level of SARS-CoV-2 RNA Time: Day 0 to Day 28Description: Comparison of participant self-assessed blood oxygen saturation levels (in percentage oxygen) between treatment arms using pulse oximetry from Day 0 to Day 28.
Measure: Change in oxygen saturation levels Time: Day 0 to Day 28Description: Secondary infection will be assessed by measuring the number of individuals that live in the same house as the active arm who became sick by the end of follow-up period.
Measure: Rate of participant-reported secondary infection of housemates Time: Up to day 90Description: Disease severity measured by time (in days) to admission to the ICU or , invasive mechanical ventilation or time to death.
Measure: Time to ICU admission, invasive mechanical ventilation or death in hospital Time: Up to day 90Description: Time (in days) to resolution of COVID-19 symptoms will be based on temperature logs and symptom score sheets.
Measure: Time to resolution of COVID-19 symptoms Time: Up to day 90Description: Assess change in hospitalization rate as measured by number of hospitalizations stratified by age groups <65 and >=65
Measure: Impact of convalescent plasma on outcome as assessed by change in hospitalization rate Time: Day 0 to Day 90Description: Impact of donor antibody titers (high/low) will be assessed by hospitalization rate as measured by number of hospitalizations.
Measure: Impact of donor antibody titers on hospitalizaton rate of convalescent plasma recipients Time: Day 0 to Day 90Description: Impact of donor antibody titers (high/low) will be assessed by antibody levels
Measure: Impact of donor antibody titers on antibody levels of convalescent plasma recipients Time: Day 0 to Day 90Description: Impact of donor antibody titers (high/low) will be assessed by viral positivity rates (number of SARS-CoV-2 positive cases per total cases)
Measure: Impact of donor antibody titers on viral positivity rates of convalescent plasma recipients Time: Day 0 to Day 90